Wockhardt rises 10% after antibiotic Zaynich, undergoing clinical trials, facilitates in a liver transplant

The drug eradicated dual extreme-drug resistant pathogens, said the Wockhardt statement and helped resume chemotherapy on the 73-year old patient.

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Wockhardt's investigational antibiotic Zaynich, undergoing Phase III clinical trials, has successfully cleared a chronic bile duct infection in USA, thus facilitating a liver transplant, the company informed on December 16. Shares of Wockhardt were higher by 10% in early trade on Monday to test a nine-year high.

The drug eradicated dual extreme-drug resistant pathogens, said the Wockhardt statement and helped resume chemotherapy on the 73-year old patient. Till date, 45 patients who were suffering from range of life-threatening Gram negative infections have benefitted under compassionate use of Zaynich. In US, compassionate use approvals for the antibiotic are provided by the FDA in the form of individual, patient-specific expanded access.

In a brief update about the case, Wockhardt shared the patient "received several broad spectrum antibiotics for >6 weeks but continued to have fever and persistent infection markers precluding liver transplant procedure. 15 days of treatment with Zaynich helped control infectious processes and cleared the way for the transplant in this patient."

Wockhardt is betting on Zaynich as part of its portfolio of novel antibiotics, that the company says are 'well-placed' to tackle the global antimicrobial resistance threat, and it among the pharma company's future growth drivers.

The shares of Wockhardt are higher by 220% so far this year and the company has a market capitalisation of nearly Rs 24,500 crore.

The investigational antibiotic categorised under the novel class of 'β-lactam enhancers', is under evaluation for its efficacy in treating complicated urinary tract infections, including acute pyelonephritis.

In May 2024, Wockhardt announced that its medicine has demonstrated a remarkable 100 percent clinical cure rate among 30 critically ill patients suffering from a variety of life-threatening, extensively drug-resistant Gram-negative infections. These patients faced a challenging array of infections, including hospital-acquired/ventilator-associated pneumonia, empyema, bloodstream infections, urosepsis, intra-abdominal infections, necrotising fasciitis, and osteomyelitis, caused by a spectrum of highly resistant Gram-negative pathogens such as Pseudomonas, Klebsiella, E coli, Acinetobacter, and Serratia.

Habil Khorakiwala, Chairman of Wockhardt had previously said that once the trials are complete, the company will seek necessary regulatory approvals and hope to be in the market 'some time in 2026'.